摘要
[目的]探讨阿帕替尼单药方案治疗进展期胃癌的疗效及预后影响因素。[方法]回顾性分析210例接受阿帕替尼单药治疗的晚期胃癌患者临床资料,总结近期疗效、生存时间及安全性指标,评价阿帕替尼单药治疗晚期胃癌的预后影响因素。[结果]210例患者治疗后客观缓解率和疾病控制率分别为5.71%和65.71%;中位无进展生存时间为73.0 d;≥3级不良反应包括:高血压6例,合并手足综合征10例,蛋白尿4例,腹泻4例,血小板减少7例,疲倦2例,出血4例。单因素分析显示,PS评分、给药剂量、合并手足综合征、高血压、蛋白尿、腹泻及AFP水平与阿帕替尼单药治疗晚期胃癌疾病控制率有关(P<0.05);多因素分析显示,PS评分、合并手足综合征、高血压及AFP水平是阿帕替尼单药治疗晚期胃癌疾病控制率独立影响因素(P<0.05)。单因素分析显示,年龄、PS评分、给药剂量、合并手足综合征、高血压、蛋白尿及AFP水平与阿帕替尼单药治疗晚期胃癌无进展生存时间有关(P<0.05);多因素分析结果显示,PS评分、给药剂量、合并手足综合征、高血压及AFP水平是阿帕替尼单药治疗晚期胃癌无进展生存时间的独立影响因素(P<0.05)。[结论]阿帕替尼单药治疗晚期胃癌疾病控制效果与PS评分、合并手足综合征、高血压及AFP水平密切相关;PS评分、给药剂量、合并手足综合征、高血压及AFP水平能够独立影响患者无进展生存时间。
[Objective]To investigate the efficacy and the prognostic factors of apatinib monotherapy in the treatment for advanced gastric cancer.[Methods]Clinical data of 210 stageⅣgastric cancer treated with apatinib monotherapy were retrospectively analyzed.The clinical efficacy,survival time and safety indexes were analyzed and the prognostic factors of apatinib monotherapy for stageⅣgastric cancer were evaluated.[Results]The objective response rate and disease control rate of 210 patients after treatment were 5.71%and 65.71%,respectively;the median progression free survival time was73.0 d.Grade 3 adverse reactions included hypertension(n=6),combined hand-foot syndrome(n=10),proteinuria(n=4),diarrhea(n=4),thrombocytopenia(n=7),fatigue(n=2)and bleeding(n=4).Univariate analysis showed that PS score,dosage,combined hand-foot syndrome,hypertension,proteinuria,diarrhea and AFP levels were associated with the disease control rate of stageⅣgastric cancer treated with apatinib monotherapy(P<0.05).Multivariate analysis showed that PS score,combined handfoot syndrome and hypertension and AFP levels were independent influencing factors for disease control rate of stageⅣgastric cancer treated with apatinib monotherapy(P<0.05).Univariate analysis showed that age,PS score,dosage,hypertension,combined hand-foot syndrome,proteinuria and AFP levels were associated with progression free survival in patients with stageⅣgastric cancer(P<0.05).Multivariate analysis showed that PS score,dosage,combined hand-foot syndrome,hypertension and AFP levels were independent factors of progression free survival in patients with stageⅣgastric cancer(P<0.05).[Conclusion]The disease control effect of apatinib monotherapy in patients with stageⅣgastric cancer is closely related to PS score,combined hand-foot syndrome,hypertension and AFP levels;PS score,dosage,combined hand-foot syndrome,hypertension and AFP levels can independently affect progression free survival time.
作者
郑华理
张煌
周帅跃
朱爱萍
ZHENG Hua-li;ZHANG Huang;ZHOU Shuai-yue;ZHU Ai-ping(The First People’s Hospital of Anqing City,Anqing 246QQQ,China)
出处
《肿瘤学杂志》
CAS
2022年第4期280-284,共5页
Journal of Chinese Oncology
